Trade Name：Xiesaiping
Generic Name：Valsartan and Hydrochlorothiazide Tablets
Manufacturer：Beijing Bioeast Pharmaceutical Co., Ltd.
Specification：80mg:12.5mg×14 tablets/box
Dosage Form：Film-coated tablets, which are white or off-white after the coating is removed
Category：Prescription drug
Approval Number：国药准字 H20203024 (H20203024 in Chinese Pharmacopoeia)
Validity Period：24 months
Storage Conditions：Store in a sealed container

It is used for the treatment of mild to moderate essential hypertension that cannot be adequately controlled by a single drug1.

Valsartan：Blocks the binding of angiotensin II to the angiotensin II type 1 receptor, thereby relaxing blood vessels and reducing blood pressure.
Hydrochlorothiazide：Acts on the distal convoluted tubule of the kidney to inhibit the reabsorption of sodium and chloride ions, increasing urine output and reducing blood volume, thus achieving the effect of reducing blood pressure. The combination of the two has a synergistic antihypertensive effect.

Take 1 tablet once a day, either before or after a meal.

Valsartan：Adverse reactions are usually rare and independent of dose. There have been rare reports including angioedema, rash, pruritus and other hypersensitivity reactions.
Hydrochlorothiazide：The main adverse reaction is hypokalemia, which is dose-related. The dose-independent adverse reactions mainly include pancreatitis. There may also be hyponatremia, hypomagnesemia, hyperuricemia, etc.

Hypersensitivity to valsartan, hydrochlorothiazide, other sulfonamide derivatives or any component of this product.
Pregnant women.
Patients with severe liver failure, biliary cirrhosis or cholestasis.
Patients with severe renal failure (creatinine clearance rate <30ml/min) or anuria.
Patients with refractory hypokalemia, hyponatremia or hypercalcemia and symptomatic hyperuricemia (history of gout or uric acid stones).

When used in combination with potassium-sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that can increase potassium levels (such as heparin), monitor potassium and magnesium levels regularly.
For patients with severe sodium and/or volume depletion, correct the condition before starting treatment.
Use with caution in patients with unilateral or bilateral renal artery stenosis or solitary renal artery stenosis.
For patients with mild to moderate renal impairment (glomerular filtration rate ≥30ml/min), no dose adjustment is required. It is not recommended for patients with severe renal impairment.

When used in combination with non-steroidal anti-inflammatory drugs, the diuretic and antihypertensive activities may be weakened, and acute renal failure may occur if there is insufficient blood volume.
When used in combination with potassium-lowering diuretics, corticosteroids, etc., the loss of potassium and/or magnesium may be aggravated.
When used in combination with lithium agents, it may cause a reversible increase in serum lithium concentration and lithium poisoning.